FibroGen Stock (NASDAQ:FGEN)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$0.40

52W Range

$0.18 - $2.93

50D Avg

$0.35

200D Avg

$0.85

Market Cap

$48.37M

Avg Vol (3M)

$1.21M

Beta

0.73

Div Yield

-

FGEN Company Profile


FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

486

IPO Date

Nov 14, 2014

Website

FGEN Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Drug Product Revenue$18.75M$11.09M$962.00K

Fiscal year ends in Dec 23 | Currency in USD

FGEN Financial Summary


Dec 23Dec 22Dec 21
Revenue$147.75M$140.73M$235.31M
Operating Income$-281.81M$-301.02M$-288.53M
Net Income$-284.23M$-295.23M$-291.03M
EBITDA$-281.81M$-282.82M$-288.53M
Basic EPS$-2.92$-3.15$-3.15
Diluted EPS$-2.92$-3.15$-3.15

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 12, 24 | 8:38 PM
Q2 24Aug 09, 24 | 11:32 AM
Q1 24May 06, 24 | 12:00 AM

Peer Comparison


TickerCompany
CGEMCullinan Oncology, Inc.
RVMDRevolution Medicines, Inc.
MRUSMerus N.V.
BPMCBlueprint Medicines Corporation
BMEABiomea Fusion, Inc.
DAWNDay One Biopharmaceuticals, Inc.
STOKStoke Therapeutics, Inc.
STROSutro Biopharma, Inc.
AKROAkero Therapeutics, Inc.
GOSSGossamer Bio, Inc.
MREOMereo BioPharma Group plc
LRMRLarimar Therapeutics, Inc.
VSTMVerastem, Inc.
BMRNBioMarin Pharmaceutical Inc.
ARDXArdelyx, Inc.
GLUEMonte Rosa Therapeutics, Inc.
SNDXSyndax Pharmaceuticals, Inc.
PCVXVaxcyte, Inc.
ZURAZura Bio Limited
LYELLyell Immunopharma, Inc.
AGIOAgios Pharmaceuticals, Inc.
HEPAHepion Pharmaceuticals, Inc.